Othman, I.; Moossavi, S.Z.; Bayati, S.; Chang, Y.S.; Sanjoy, S.; Grzyb, K.; Sy, E.; Cropper, K.; Kassir, S.; Sabry, W.
Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting. Curr. Oncol. 2025, 32, 296.
https://doi.org/10.3390/curroncol32060296
AMA Style
Othman I, Moossavi SZ, Bayati S, Chang YS, Sanjoy S, Grzyb K, Sy E, Cropper K, Kassir S, Sabry W.
Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting. Current Oncology. 2025; 32(6):296.
https://doi.org/10.3390/curroncol32060296
Chicago/Turabian Style
Othman, Ibraheem, Seyedeh Zahra (Mona) Moossavi, Samaneh Bayati, Yi Sin Chang, Shubrandu Sanjoy, Karolina Grzyb, Eric Sy, Kayla Cropper, Sandy Kassir, and Waleed Sabry.
2025. "Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting" Current Oncology 32, no. 6: 296.
https://doi.org/10.3390/curroncol32060296
APA Style
Othman, I., Moossavi, S. Z., Bayati, S., Chang, Y. S., Sanjoy, S., Grzyb, K., Sy, E., Cropper, K., Kassir, S., & Sabry, W.
(2025). Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting. Current Oncology, 32(6), 296.
https://doi.org/10.3390/curroncol32060296
